2 Must-Have Biotechs For The Rest Of 2017

2 Must-Have Biotechs For The Rest Of 2017


Biotech has had a nice surge in February. Small- and mid-caps are leading the charge as M&A activity has picked up markedly so far in 2017.



from Biotech News